GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.11.24	Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan (EN, GlaxoSmithKline)
19.11.24	Company statement: GSK continues to show strong leadership in its Access to Medicines Index ranking (EN, GlaxoSmithKline)
19.11.24	Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking (EN, GlaxoSmithKline)
19.11.24	Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
14.11.24	Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
13.11.24	GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need (EN, GlaxoSmithKline)
12.11.24	New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers (EN, GlaxoSmithKline)
30.10.24	GSK on track to deliver 2024 outlooks with further good progress made in R&D (EN, GlaxoSmithKline)
29.10.24	GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline (EN, GlaxoSmithKline)
24.10.24	New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease (EN, GlaxoSmithKline)
24.10.24	New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease (Businesswire)
21.10.24	GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease (EN, GlaxoSmithKline)
16.10.24	ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024 (EN, GlaxoSmithKline)
16.10.24	Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents (EN, GlaxoSmithKline)
14.10.24	GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
10.10.24	GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 (EN, GlaxoSmithKline)
09.10.24	Statement: Zantac (ranitidine) litigation - settlement agreements reached (EN, GlaxoSmithKline)
08.10.24	GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons (EN, GlaxoSmithKline)
08.10.24	GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons (Businesswire)
07.10.24	ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries (EN, GlaxoSmithKline)
24.09.24	GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion (EN, GlaxoSmithKline)
18.09.24	Statement: Zantac (ranitidine) litigation - Russell and Hughes cases (EN, GlaxoSmithKline)
18.09.24	GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX (Businesswire)
17.09.24	Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan (EN, GlaxoSmithKline)
13.09.24	Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
12.09.24	GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme (EN, GlaxoSmithKline)
11.09.24	GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial (EN, GlaxoSmithKline)
09.09.24	Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations (EN, GlaxoSmithKline)
06.09.24	GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD (EN, GlaxoSmithKline)
03.09.24	GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress (EN, GlaxoSmithKline)
29.08.24	European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
28.08.24	GSK’s Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
27.08.24	Statement: Zantac (ranitidine) litigation - Delaware Supreme Court to review Superior Court’s Daubert decision (EN, GlaxoSmithKline)
20.08.24	GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer (EN, GlaxoSmithKline)
15.08.24	Statement: Zantac (ranitidine) litigation - Florida State Court Daubert Ruling in Wilson case (EN, GlaxoSmithKline)
05.08.24	Statement: Zantac (ranitidine) litigation - Joiner case (EN, GlaxoSmithKline)
31.07.24	GSK delivers continued strong performance and upgrades 2024 guidance (EN, GlaxoSmithKline)
30.07.24	GSK presents new data at the Alzheimer's Association International Conference 2024 (EN, GlaxoSmithKline)
29.07.24	Arexvy, GSK’s Respiratory Syncytial Virus (RSV) vaccine, receives positive European Medicines Agency CHMP opinion for adults aged 50-59 at increased risk for RSV disease (EN, GlaxoSmithKline)
23.07.24	ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor (EN, GlaxoSmithKline)
23.07.24	ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 (EN, GlaxoSmithKline)
23.07.24	ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024 (EN, GlaxoSmithKline)
19.07.24	Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency (EN, GlaxoSmithKline)
15.07.24	ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024 (EN, GlaxoSmithKline)
05.07.24	Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria (EN, GlaxoSmithKline)
03.07.24	GSK and CureVac to restructure collaboration into new licensing agreement (EN, GlaxoSmithKline)
28.06.24	Statement: Zantac (ranitidine) litigation - Gross case (EN, GlaxoSmithKline)
26.06.24	Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season (EN, GlaxoSmithKline)
24.06.24	Jemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
10.06.24	Statement: Zantac (ranitidine) litigation - Kasza case (EN, GlaxoSmithKline)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

27.07.22		GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an
18.07.22		Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt
23.06.22		GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen
06.06.22		GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten
01.06.22		GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus
31.05.22		GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal
27.04.22		GSK-Aktie höher: GlaxoSmithKline übertrifft Gewinnerwartungen
27.04.22		Ausblick: GlaxoSmithKline gewährt Anlegern Blick in die Bücher

27.07.22

GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an

18.07.22

Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt

23.06.22

GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen

06.06.22

GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten

01.06.22

GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus

31.05.22

GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal